(Q34887797)

5 August 2017

1 reference

title

5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications (English)

1 reference

5 August 2017

J Dörsam

1

1 reference

5 August 2017

J Altwein

series ordinal

2

1 reference

5 August 2017

publication date

25 November 2008

1 reference

Prostate Cancer and Prostatic Diseases

5 August 2017

published in

1 reference

5 August 2017

volume

12

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

130-136

1 reference

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Steroid 5 alpha-reductase: two genes/two enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia Epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

5alpha-reductase activity in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Clinical pharmacokinetics and pharmacodynamics of finasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Prevention of benign prostatic hyperplasia disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Can prostate cancer be prevented?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Does finasteride alter the pathology of the prostate and cancer grading?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The influence of prostate size on cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The clinical implications of the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The androgen axis in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Assessment of prostate carcinoma in core needle biopsy--definition of minimal criteria for the diagnosis of cancer in biopsy material

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.56

31 March 2020

Identifiers

DOI

10.1038/PCAN.2008.56

1 reference

5 August 2017

1 reference